Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
02 Febbraio 2024 - 4:40PM
Edgar (US Regulatory)
Filed
Pursuant to Rule 433 Under the Securities Act of 1933, as amended
Issuer
Free Writing Prospectus dated February 2, 2024
Relating
to Prospectus Supplement dated February 2, 2024
to
Prospectus dated July 20, 2023
Registration
Statement No. 333-272534
Uranium
Royalty Corp.
US$22.9
Million Public Offering of Common Shares
February
2, 2024 |
A
final base shelf prospectus and a shelf prospectus supplement containing important information relating to the securities described
in this document have been filed with the securities regulatory authorities in each of the provinces and territories of Canada, other
than Quebec (the “Canadian Qualifying Jurisdictions”), and a corresponding registration statement on Form F-10 (SEC File
No. 333-272534) has been filed with the United States Securities and Exchange Commission (“SEC”).
You
may get these documents and any applicable shelf prospectus supplement for free by visiting EDGAR on the SEC’s website at www.sec.gov
or SEDAR+ at www.sedarplus.ca. Alternatively, copies of these documents and any applicable shelf prospectus supplement can be obtained
by contacting the Company (defined below) or, in Canada from Canaccord Genuity Corp., 40 Temperance Street, Suite 2100, Toronto,
ON M5H 0B4 and in the United States from Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, Massachusetts 02110, Attn: Syndicate
Department, by telephone at (617) 371-3900, or by email at prospectus@canaccordgenuity.com.
This
document does not provide full disclosure of all material facts relating to the Common Shares. Investors should read the final base
shelf prospectus, any amendment thereto and any applicable shelf prospectus supplement, for disclosure of those facts, especially
risk factors relating to the Common Shares, before making an investment decision.
All
amounts in US$ unless otherwise stated.
|
Issuer: |
Uranium
Royalty Corp. (the “Company”) |
|
|
Underwritten
Offering: |
6,724,600
common shares of the Company (the “Common Shares”). |
|
|
Offering
Price: |
US$3.40
per Common Share (the “Offering Price”). |
|
|
Gross
Proceeds: |
US$22,863,640
(US$26,293,186 upon exercise in full of the Over-Allotment Option as defined below). |
|
|
Over-Allotment
Option: |
The
Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 1,008,690
Common Shares at US$3.40 per Common Share, exercisable in whole or in part at any time, for a period of 30 days after and including
the Closing Date (as defined herein) (the Over-Allotment Option together with the Underwritten Offering shall be collectively referred
to as the “Offering”). |
|
|
Use
of Proceeds: |
The
net proceeds of the Offering will be used to fund future royalty acquisitions and purchases of physical uranium. |
|
|
Form
of Offering: |
“Bought-deal”
public offering by way of a prospectus supplement to the Company’s short form base
shelf prospectus dated July 20, 2023, to be filed in all of the provinces and territories
of Canada, other than Quebec, and as a registered public offering in the United States under
the multijurisdictional disclosure system. In jurisdictions outside of Canada and the United
States, as approved by the Company, acting reasonably, in accordance with all applicable
laws provided that the registration of the Common Shares in such jurisdiction will not be
required, no prospectus, registration statement or similar document is required to be filed
in such jurisdiction and the Company will not be subject to any continuous disclosure requirements
in such jurisdiction.
|
Underwriting
Agreement |
The
Company and the Underwriters will enter into a definitive underwriting agreement which agreement
will contain “material change out”, “disaster and regulatory out”,
and “breach out” clauses running to the closing of the Offering.
|
Listing: |
An
application will be made to list the Common Shares on the TSX Stock Exchange (the “TSX”) and Nasdaq Capital Market (“Nasdaq”).
The existing common shares are listed on the TSX under the symbol “URC” and on Nasdaq under the symbol “UROY”. |
|
|
Eligibility: |
The
Common Shares shall be eligible for RRSPs, RRIFs, RESPs, RDSPs, TFSAs and DPSPs. |
|
|
Joint
Bookrunners: |
Canaccord
Genuity Corp. and BMO Capital Markets. |
|
|
Underwriters’
Commission: |
Cash
commission equal to 5.5%. |
|
|
Closing
Date: |
February
9, 2024 or such other date as Canaccord Genuity and the Company may agree. |
Grafico Azioni Uranium Royalty (NASDAQ:UROY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Uranium Royalty (NASDAQ:UROY)
Storico
Da Feb 2024 a Feb 2025